Next Phase Newsletter

A venture capital firm headquartered in Western Europe closed their first fund in 2012 and the portfolio companies have advanced into clinical stages, raised additional funding and one of the companies has recently completed an exit. The firm recently raised a second fund for Pre-Seed, Seed, and Series A investments with a focus in technology transfer in all four life science sectors. The firm invests €1-2M as a seed investment in the form of equity or convertible notes to help companies advance into preclinical proof of concept, and can continue investing up to €6M. If additional funds are needed, the firm seeks co-investments from the strong network of investors they have in Europe. The firm is also looking to expand this network into the US as well. The firm is looking for investments across Europe.

The firm invests in all four life science sectors, but has a particular focus on therapeutics. Within therapeutics the firm has an interest in cutting edge technologies in advanced therapies, gene and cell therapy, gene editing and synthetic biology. The firm is agnostic to subsector and indication and will invest in pre-clinical companies and follow the companies through the development of the project with additional investors. The firm is open to all 3 classes of medical devices.

The firm looks for companies with a scientific founder, and preferably a C Level executive with a track record in biotech or pharmaceutical companies. The firm prefers to lead or co-lead in Seed stage therapeutics companies and will seek a board seat. The firm will co-invest in medtech investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture fund based in USA for their first fund and will invest from early to later stage companies. The firm is interested in therapeutics, companion diagnostics, precision medicine, tools and manufacturing services. The firm generally invests $10M or more, but may participate in earlier rounds, primarily as a fund of funds. The firm will invest globally, and prefers companies developing platform technologies or with multiple assets.

Within therapeutics, the firm is interested in small molecules, biologics and cell and gene therapies. Outside of therapeutics, the firm is interested in companion diagnostics, precision medicine, life science tools, and novel manufacturing technologies. Indications of interest include oncology/IO, neurodegeneration, autoimmune disorders, cardiometabolic disorders and rare diseases. The firm is willing to invest from pre-IND all the way to PIPEs.

The firm is willing to lead or co-invest, but is a very active investor, and will take at least one board seat after investment. As an individual investor, the firm prefers to invest at least $10M per company, but may invest in smaller rounds as an LP of another investment firm.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Life Science focused private equity and venture capital firm based in Asia is also the co-manager of another life sciences focused fund. The firm is an evergreen fund, and generally makes longer term investments than a typical VC.  The firm does not make seed investments, but is interested in both early stage venture capital investments and late stage companies seeking growth and expansion capital. Typically, the firm invests USD 5-15 million per opportunity. The firm can invest globally and is actively seeking new investment opportunities.

The firm seeks to invest in breakthrough healthcare biotech, medical devices, diagnostics, healthcare IT, and biorenewable and bioindustrial technologies. The firm is open to a wide range of technologies including novel techniques such as stem cells and genomics, and will consider investing in any area of medicine. The firm prefers to invest in technologies that have attained clinical validation.

The firm seeks a strong and experienced management team. The firm may take a board seat on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office located in USA and is focused on helping female founders raise capital in the women’s health space. The firm typically makes investments ranging from $10-25K in the form of equity, convertible notes and SAFE notes. The firm planning to raise their first fund in 2022. The firm invests in both Pre-Seed and Seed rounds and invests in the US market.

The firm invests in seed stage, preferably in companies focused on women’s health. Within that arena, the firm is open to all 4 sectors and subsectors as they relate to women’s health and is agnostic to disease indication as well. The firm is not interested in pre-clinical or pre-prototype companies but is open to all three classes of medical devices on a case-by-case basis.

The firm is only interested in working with companies with female founders. With that being said, the firm is open to all types of management teams and is looking for companies that are working to improve patient outcomes. The firm is interested in co-investing and does not lead.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in California backs entrepreneurs applying deep and differentiated technology to transform giant industries. The firm focuses on seed and series A investments and has over $2B AUM. The firm usually makes seed investments in the range of $250K – $1M and venture-stage investments from $1M-$4M and may use both convertible notes or straight equity. The firm may lead or co-invest in a syndicate and looks to add unique value to entrepreneurs with a strong Equity Partner network, operational experience and technical background.

The firm invests in several verticals and is focused on deep technologies such as AI, advanced materials, quantum computing, etc. In the healthcare space, the firm is focused on the entire continuum including computational drug discovery, AI-driven diagnostics, better/faster clinical trials and technologies used by payers and providers to better understand and manage risk and drive better outcomes. The common theme is that the startup’s underlying technology be novel and data-driven. The firm does not invest in biopharma or traditional medical devices/diagnostics with a standard regulatory pathway.

The firm requires that startups have some type of proof-of-concept and traction, and prefers experienced/proven management teams and entrepreneurs that are introduced through the firm’s network. The firm typically seeks a board seat when leading an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A family office based in New York, NY is looking to invest in medical devices and diagnostics, but will also consider therapeutics and digital health. The firm prefers companies that have some proof of concept data, with some animal studies complete, and will invest through to clinical-stage companies. The firm generally co-invests in a syndicate, and will invest between $100-500K, depending on the stage of development of the company. The firm is currently interested in investing in companies located in North America.

The firm is focused primarily on medical devices and diagnostics, but will consider therapeutics, if they are first in class, and digital health, with a focus on AI-related technologies. The firm has focused on technologies related to oncology, diabetes and kidney diseases, but will consider other indications as well.

The firm is interested in companies with strong management teams. As the firm will generally co-invest, board representation is not usually required after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A newly established venture capital firm founded in 2020 and is based in Barcelona, Spain. The firm is currently raising its first fund targeting €30M, and expects to close in mid to late 2021 and become fully operative. The firm is actively seeking investment opportunities and performing due diligence on companies they identify as a fit with the firm. The firm’s focus is in Seed to Series A financings and initial size of investment will be around €500K, and can invest up to €2.5M over the life of investment. The firm is open to USA-based opportunities but will focus on those based in Europe, Israel, and Spain where the firm is based.

The firm is exclusively interested in companies in the longevity space. In this regard, the firm is most interested in digital technologies including AI, robotics, data analytics, etc. Traditional therapeutics or devices do not fall within their investment priority, as the firm prefers to seek opportunities that leverage digital technologies to deliver novel therapeutic solutions (i.e. digital therapeutics). The firm is open to very early-stage, pre-revenue technologies and are open to university spin-offs/tech transfers.

The firm is backed by co-founders who have entrepreneurial backgrounds and can be a hands-on investor, assisting with company creation and other support as needed. When investing in companies that are not in geographical proximity to the firm, the firm prefers to co-invest alongside larger VC firms.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.